Phase I/II study of Taxotere (docetaxel), Eloxatin (oxaliplatin) and Xeloda (capecitabine) as first line treatment to patients with non-resectable ventricular cancer and/or distal esophageal cancer.

Trial Profile

Phase I/II study of Taxotere (docetaxel), Eloxatin (oxaliplatin) and Xeloda (capecitabine) as first line treatment to patients with non-resectable ventricular cancer and/or distal esophageal cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Nov 2012

At a glance

  • Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Oxaliplatin (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top